bluebird bio, Inc. (NASDAQ:BLUE) Receives Average Rating of “Hold” from Analysts

Shares of bluebird bio, Inc. (NASDAQ:BLUE) have been given an average rating of “Hold” by the eight research firms that are presently covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $44.60.

Several equities research analysts have issued reports on the stock. Barclays lowered their price target on shares of bluebird bio from $40.00 to $8.00 and set an “overweight” rating on the stock in a report on Monday. Baird R W cut shares of bluebird bio from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 21st. StockNews.com began coverage on shares of bluebird bio in a research report on Friday, March 28th. They issued a “sell” rating for the company. JPMorgan Chase & Co. raised bluebird bio from an “underweight” rating to a “neutral” rating in a report on Monday, February 24th. Finally, Wells Fargo & Company lowered their price objective on bluebird bio from $40.00 to $5.00 and set an “equal weight” rating on the stock in a research note on Monday, February 24th.

bluebird bio Stock Performance

BLUE opened at $4.89 on Friday. The stock’s 50 day simple moving average is $5.29 and its 200-day simple moving average is $7.59. The company has a current ratio of 0.51, a quick ratio of 0.33 and a debt-to-equity ratio of 0.37. The stock has a market cap of $47.87 million, a PE ratio of -0.13 and a beta of 0.41. bluebird bio has a 1 year low of $3.56 and a 1 year high of $28.60.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Regeneron Pharmaceuticals Inc. acquired a new stake in bluebird bio during the 4th quarter valued at $175,000. Barclays PLC grew its holdings in shares of bluebird bio by 273.7% during the third quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock worth $130,000 after purchasing an additional 184,605 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of bluebird bio by 3.7% in the third quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company’s stock valued at $2,433,000 after buying an additional 166,771 shares in the last quarter. State Street Corp raised its holdings in shares of bluebird bio by 1.1% in the third quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company’s stock valued at $1,996,000 after buying an additional 43,382 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in shares of bluebird bio by 2,270.2% in the third quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company’s stock valued at $193,000 after buying an additional 355,562 shares during the last quarter. Institutional investors own 87.43% of the company’s stock.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.